VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.

Watanabe, Hiromi; Ichihara, Eiki; Kayatani, Hiroe; Makimoto, Go; Ninomiya, Kiichiro; Nishii, Kazuya; Higo, Hisao; Ando, Chihiro; Okawa, Sachi; Nakasuka, Takamasa; Kano, Hirohisa; Hara, Naofumi; Hirabae, Atsuko; Kato, Yuka; Ninomiya, Takashi; Kubo, Toshio; Rai, Kammei; Ohashi, Kadoaki; Hotta, Katsuyuki; Tabata, Masahiro; Maeda, Yoshinobu; Kiura, Katsuyuki

Watanabe, Hiromi; Ichihara, Eiki; Kayatani, Hiroe; Makimoto, Go; Ninomiya, Kiichiro; Nishii, Kazuya; Higo, Hisao; Ando, Chihiro; Okawa, Sachi; Nakasuka, Takamasa; Kano, Hirohisa; Hara, Naofumi; Hirabae, Atsuko; Kato, Yuka; Ninomiya, Takashi; Kubo, Toshio; Rai, Kammei; Ohashi, Kadoaki; Hotta, Katsuyuki; Tabata, Masahiro; Maeda, Yoshinobu; Kiura, Katsuyuki.

Affiliation

Watanabe H; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Ichihara E; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Kayatani H; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Makimoto G; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Ninomiya K; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Nishii K; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Higo H; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Ando C; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Okawa S; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Nakasuka T; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Kano H; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Hara N; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Hirabae A; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Kato Y; Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
Ninomiya T; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Kubo T; Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan.
Rai K; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Ohashi K; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Hotta K; Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
Tabata M; Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan.
Maeda Y; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Kiura K; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

Cancer Sci ; 112(5): 1853-1864, 2021 May.

Article in En | MEDLINE | ID: mdl-33410241

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy; Lung Neoplasms/drug therapy; Molecular Targeted Therapy/methods; Neovascularization, Pathologic/prevention & control; Protein Kinase Inhibitors/therapeutic use; Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors; A549 Cells; Acrylamides/therapeutic use; Anaplastic Lymphoma Kinase/genetics; Aniline Compounds/therapeutic use; Animals; Antibodies, Monoclonal/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Carbazoles/therapeutic use; Carcinoma, Non-Small-Cell Lung/genetics; Carcinoma, Non-Small-Cell Lung/metabolism; Cell Line, Tumor; Combined Modality Therapy/methods; Crizotinib/therapeutic use; Drug Synergism; Erlotinib Hydrochloride/therapeutic use; Female; Genes, erbB-1; Heterografts; Humans; Lung Neoplasms/genetics; Lung Neoplasms/metabolism; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Oncogenes; Piperidines/therapeutic use; Platelet Endothelial Cell Adhesion Molecule-1/analysis; Protein-Tyrosine Kinases/genetics; Proto-Oncogene Proteins/genetics; Random Allocation; Signal Transduction/drug effects; Vascular Endothelial Growth Factor Receptor-2/metabolism; Ramucirumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Angiogenesis Inhibitors / Vascular Endothelial Growth Factor Receptor-2 / Protein Kinase Inhibitors / Molecular Targeted Therapy / Lung Neoplasms / Neovascularization, Pathologic Type of study: Clinical_trials / Prognostic_studies Language: En Journal: Cancer Sci Year: 2021 Type: Article Affiliation country: Japan

Fulltext

XML

PubMed Links

Search on Google